Health & Research Goals
Selank
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Russia and approved for the treatment of generalized…
Primary Description
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed in Russia and approved for the treatment of generalized anxiety disorder (GAD). It is a structural analogue of tuftsin, an endogenous immunomodulatory tetrapeptide. Unlike traditional anxiolytics such as benzodiazepines, Selank produces anxiolytic effects without sedation, cognitive impairment, or dependence potential. It is primarily administered intranasally to bypass the blood-brain barrier and has a short half-life requiring multiple daily doses. Selank is widely regarded by clinicians and researchers for its unique ability to reduce anxiety while simultaneously enhancing cognition and providing neuroprotective effects.
Key Benefits
- Anxiety reduction
- Mood enhancement
- Cognitive support
Store refrigerated at 2–8°C. Reconstituted solution stable for up to 30 days when refrigerated. Protect from light. Available as nasal spray solution or lyophilized powder for reconstitution with bacteriostatic water.
Demonstrated Effects
- Reduces anxiety and stress without sedation or cognitive impairment
- Approved in Russia for generalized anxiety disorder (GAD) treatment
- Enhances memory consolidation, attention, and learning capacity
- Provides neuroprotection against oxidative stress and excitotoxicity
- Modulates BDNF expression supporting neuroplasticity
- No reported dependence, tolerance, or withdrawal syndrome
- Immunomodulatory effects via tuftsin-like activity
- Protects against ethanol-induced cognitive impairment
- May enhance mood stability and emotional resilience
- Compatible with concurrent use without significant drug interactions
Proposed Mechanisms of Action
1. Opioid and Serotonin System Modulation
Selank interacts with opioid receptors and modulates serotonin metabolism, contributing to its anxiolytic and mood-stabilizing effects without producing dependency or euphoria.
2. BDNF/trkB Pathway Activation
Upregulates brain-derived neurotrophic factor (BDNF) expression, enhancing neuroplasticity, memory consolidation, and neuroprotection. This is the primary mechanism for cognitive enhancement.
3. Tuftsin-like Immunomodulation
As a structural analogue of tuftsin, Selank modulates cytokine production, regulates neuroinflammation, and exerts immunostimulatory effects on the innate immune system.
4. Enkephalin Degradation Inhibition
Selank inhibits the degradation of enkephalins (endogenous opioid peptides), prolonging their anxiolytic and mood-enhancing effects without direct opioid receptor activation.
5. Dopamine and Norepinephrine Modulation
Modulates catecholaminergic neurotransmission contributing to improved attention, motivation, and stress resilience without stimulant side effects.
Research Evidence & Clinical Data
Investigated Applications
Anxiety Reduction and GAD Treatment
Anecdotal: HighSelank's primary and most well-documented use is in reducing generalized anxiety. Clinical trials in Russia demonstrate efficacy comparable to benzodiazepines in GAD patients, with rapid onset and no sedation or addiction risk. Community users report consistent anxiolytic effects within 15–30 minutes of intranasal dosing.
Preclinical basis: Multiple Russian clinical trials (Volkova 2016, Zozulia 2008) confirmed GAD efficacy. Animal models show dose-dependent anxiolysis in elevated-plus-maze without motor impairment.
Cognitive Enhancement and Nootropic Use
Anecdotal: ModerateBeyond anxiolysis, Selank is valued for its cognitive-enhancing properties. Users report improved focus, mental clarity, and memory retention. BDNF modulation is considered the primary mechanism supporting neuroplasticity and learning.
Preclinical basis: Kolik 2019 demonstrated BDNF-mediated neuroprotection and cognitive-stimulating effects. Ashmarin 2004 showed Selank modulates gene expression related to neurotransmission.
Neuroprotection
Anecdotal: EmergingSelank shows promise as a neuroprotective agent against oxidative neuronal damage and excitotoxicity. Particularly studied in the context of alcohol-induced cognitive impairment and age-related cognitive decline prevention.
Preclinical basis: Ashmarin 2007 showed Selank protects against oxidative neuronal damage in vitro and in vivo. Kolik 2019 confirmed BDNF-mediated neuroprotection against ethanol toxicity.
Immunomodulation
Anecdotal: LowAs a tuftsin analogue, Selank exerts immunomodulatory effects including cytokine regulation and modulation of neuroinflammation. Clinical significance in healthy individuals is uncertain but may be relevant in chronic stress or inflammatory conditions.
Preclinical basis: Zolotarev 2012 described Selank's tuftsin-like cytokine regulation and neuroinflammation modulation.
Scientific References
- 1.[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]Zh Nevrol Psikhiatr Im S S Korsakova2008
- 2.
Safety Profile
Common Side Effects
- Mild fatigue (rare)
- Nasal irritation from intranasal administration
- Transient headache (infrequent)
- Mild drowsiness at high doses
- Minimal
- Fatigue (rare)
Contraindications
- Hypersensitivity to any component
- Pregnancy and breastfeeding (insufficient data)
- Children (insufficient safety data)
- Concurrent use with other GABAergic drugs should be monitored
- None well-established
Legal & Regulatory Status
Approved in Russia as a prescription medication for generalized anxiety disorder under the brand name Selank. Not FDA-approved in the United States. Available as a research compound in many countries. Not scheduled as a controlled substance in most jurisdictions.
Aprobado en Rusia como medicamento de prescripción para el trastorno de ansiedad generalizada bajo la marca Selank. No aprobado por la FDA en Estados Unidos. Disponible como compuesto de investigación en muchos países. No está catalogado como sustancia controlada en la mayoría de jurisdicciones.
Research Protocols
Dosing Protocols
Routes of Administration
intranasal
subcutaneous
Reconstitution Guide
Pharmacokinetics
| Half-Life | Approximately 2–3 minutes in plasma; brief systemic half-life. Intranasal route provides direct CNS delivery bypassing rapid peripheral degradation. |
Monitoring & Risk Management
Ongoing Monitoring Steps
- Monitor anxiety symptoms and cognitive function
- Assess for any dependence behaviors (rare but monitor)
- Review for nasal irritation if using intranasal route
- Periodic reassessment of therapeutic goals every 4–6 weeks
Critical Warning Signs
- Increased anxiety or paradoxical stimulation
- Significant mood changes or emotional blunting
- Nasal bleeding or severe irritation
- Serotonergic symptoms if combined with SSRIs (monitor carefully)
Featured in Stacking Protocols
Community-researched combinations involving this compound